Close Menu
Inverness Counters Beckman Bid for Biosite
Beckman Coulter has a rival suitor for Biosite’s attention.
This week, Biosite said it has received an unsolicited bid of $90 per share from Inverness Medical Innovations for the company, a $5 per share improvement over Beckman’s offer of $85 per share made on March 25.
Inverness holds 4.9 percent of Biosite shares and would purchase all remaining outstanding shares of Biosite’s stock.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An analysis of blood donations suggests SARS-CoV-2 was present in the US weeks earlier than thought, according to NPR.

The Guardian reports that DeepMind Technologies' AlphaFold can predict how proteins fold.

CNBC reports that a US Centers for Disease Control and Prevention advisory panel is to vote on how to distribute COVID-19 vaccines.

In PNAS this week: targeting progesterone signaling in ovarian cancer, LINE-1 retrotransposition events in adenocarcinomas, and more.